ReviewFrontiers in oncology2023

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression.

Malek Horani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.